Comparative Pharmacology
Head-to-head clinical analysis: PEN VEE K versus PENICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEN VEE K versus PENICILLIN VK.
PEN-VEE K vs PENICILLIN-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Penicillin VK inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
250-500 mg orally every 6-8 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections (e.g., streptococcal pharyngitis, skin infections).
None Documented
None Documented
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
0.5 hours (normal renal function); prolonged to 3-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Renal: 20-40% unchanged via tubular secretion; hepatic metabolism to penicilloic acid; biliary/fecal: minimal (<5%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic